TACR1 and colitis: Koon et al. reported that after DSS removal for an additional 5 days, mice exhibited reduced colitis scores and mild body weight loss, whereas mice treated with the NK-1R antagonist during the recovery phase showed increased colitis clinical scores and further decreased body weight, indicating the therapeutic effects of SP in the recovery phase of colitis 54.